metronidazole has been researched along with Carcinoma, Bronchogenic in 2 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the risk of occurrence of cancer associated with exposure to metronidazole in the 771 female residents of Rochester, Minnesota, who were treated with metronidazole for vaginal trichomoniasis during the period 1960 through 1969 and were followed up for a total of 12,628 person-years." | 1.27 | Cancer after exposure to metronidazole. ( Beard, CM; Dahlin, DC; Kurland, LT; Noller, KL; O'Fallon, WM, 1988) |
| "Metronidazole was administered orally to 25 patients and its maximum concentration in blood and tumor tissues, its ability to cross the blood/brain barrier and concentrate in the cerebrospinal fluid and brain tumor tissue, its immediate and long-term toxicity, and its enhancement of irradiation in normal tissue were studied." | 1.25 | Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells. ( Band, P; Chapman, JD; Fryer, CG; Rabin, HR; Sturmwind, J; Urtasun, RC, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urtasun, RC | 1 |
| Chapman, JD | 1 |
| Band, P | 1 |
| Rabin, HR | 1 |
| Fryer, CG | 1 |
| Sturmwind, J | 1 |
| Beard, CM | 1 |
| Noller, KL | 1 |
| O'Fallon, WM | 1 |
| Kurland, LT | 1 |
| Dahlin, DC | 1 |
2 other studies available for metronidazole and Carcinoma, Bronchogenic
| Article | Year |
|---|---|
Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells.
Topics: Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Mediasti | 1975 |
Cancer after exposure to metronidazole.
Topics: Carcinoma, Bronchogenic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Metronidazole; Minnesota | 1988 |